MRK.US Weekly Report · 2026-W29
Overview
Merck shares rose 3.21% this week, closing at $127.50, driven primarily by FDA approval of LIPFENDRA®, the first oral PCSK9 inhibitor, and breakthrough clinical data for Keytruda across multiple cancer indications. Despite significant institutional capital outflow, the company’s tangible new product pipeline and extremely depressed valuation multiples create an intriguing structural contrast worthy of observation.
Price Action
The stock closed at $127.50, up $3.96 from the previous week’s close on July 10 ($123.54), representing a weekly gain of 3.21%. Intraweek range: high $131.74, low $127.03, amplitude 3.68%, reflecting a measured pullback after a breakout. Trading volume reached 13.47 million shares for the week, generating $1.74 billion in turnover. Compared to the 60-day average daily volume of approximately 8-10 million, this week was notably elevated, signaling increased market attention to new product approval and clinical data. The price pattern on July 16 shows a classic bullish gap-open continuation, followed by modest consolidation on July 17 with support maintained—indicting that buying interest peaked at the news event but has not reversed the trend.
Valuation & Earnings
Current P/E of 35.24x sits at the 3.62nd percentile over the past 5 years—meaning the stock has traded cheaper (relative to earnings) 96% of the time over that period. This is a materially depressed valuation level. Price-to-book stands at 18.58 (book value per share $1.27 × price $127.50), positioned in the low-to-mid range historically.
TTM (trailing twelve-month) EPS of 3.618 contrasts sharply with consensus forecast EPS mean of 6.126 for 2026, a 69% step-up in expectations. This gap likely reflects market repricing for LIPFENDRA® commercial contribution and Keytruda indication expansion. The magnitude of this expectations revision is significant and depends on execution.
Capital Flow & Institutional View
Capital flow reveals stark divergence. Large institutional investors recorded net outflow of $686.96 this week, while retail investors showed cumulative net inflow of $1,891.27. Mid-sized institutions are near-neutral (inflow $3,888.02 vs. outflow $3,541.50). This pattern suggests selective institutional pressure against continued enthusiasm, while retail sentiment remains anchored to the positive headline flow.
Institutional rating distribution for this period is not provided, but recent traceable research shows RBC Capital maintaining a Buy rating with a 12-month price target of $137, implying 7.4% upside from current levels. Rating momentum is a lagging indicator and must be contextualized against fresh clinical and regulatory developments.
Weekly News Themes
News flow this week concentrated on three pillars:
New Product Approval: FDA greenlit LIPFENDRA® (enlicitide) as the first once-daily oral PCSK9 inhibitor for treating hypercholesterolemia in adults, filling a gap in Merck’s cardiovascular portfolio and signaling expansion into cardiology from its traditional oncology base.
Tumor Pipeline Advancement: Keytruda (pembrolizumab) met primary endpoints in Phase 3 trials across endometrial and bladder cancer indications; partner Kelun-Biotech announced positive lung cancer combination results, broadening the immunotherapy footprint across multiple cancer types.
M&A Exploration: The company is reportedly actively bidding in a competitive takeover process for genomics firm Personalis, reflecting strategic intent to expand into personalized medicine and genetic sequencing.
Key news items (ranked by relevance):
- MSD wins FDA approval for cholesterol pill to help plug Keytruda void
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA
- Merck Climbs 3% to Record After FDA Approves Oral Cholesterol Drug
- Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.
- BUZZ-Merck rises as Keytruda meets main goal in late-stage uterine cancer trial
- BUZZ-Merck rises after partner Kelun-Biotech reports positive Keytruda lung cancer study
- Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement
- RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
- Merck Buy Rating Reiterated as sac-TMT Data De-Risk Oncology Pipeline; 12-Month Price Target Maintained at $137
- UnitedHealth, Merck Share Gains Contribute To Dow’s 166-Point Jump
Signal Coherence
The week presents a core structural tension: rock-bottom valuation + product/pipeline tailwinds vs. institutional capital flight.
On one side: P/E at 35.24x is at an extreme low (3.6th percentile), consensus EPS expectations up 69%, new product approval and clinical data breakthroughs are tangible positives, and institutional research maintains buy ratings. These point toward multiple expansion opportunity.
On the other: large institutional money chose net outflow over the week. Two interpretations coexist: (1) profit-taking after headline realization, or (2) insufficient near-term catalyst visibility; institutions prefer to wait for earnings confirmation in the next quarter. Retail inflows directly counterpose institutional outflows, creating structural capital divergence.
This is neither a clean bullish nor bearish signal—it represents the market’s dynamic repositioning as it digests new product approval and awaits Q2/Q3 earnings evidence of profit delivery.